Literature DB >> 27503872

Psychotic disorders induced by antiepileptic drugs in people with epilepsy.

Ziyi Chen1, Ana Lusicic2, Terence J O'Brien3, Dennis Velakoulis2, Sophia J Adams2, Patrick Kwan4.   

Abstract

Antiepileptic drug treatment can induce psychosis in some patients. However, there are no agreed definitions or diagnostic criteria for antiepileptic drug-induced psychotic disorder in the classification systems of either epileptology or psychiatry. In this study we investigated the clinical spectrum of antiepileptic drug-induced psychotic disorder in patients with epilepsy. The medical records of all patients with epilepsy who were diagnosed by a neuropsychiatrist as having a psychotic disorder at the Royal Melbourne Hospital from January 1993 to June 2015 were reviewed. Data were extracted regarding epilepsy and its treatment, psychotic symptoms profile and outcome. The diagnosis of epilepsy was established in accordance to the classification system of the International League Against Epilepsy while that of psychotic disorder was made according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition and the proposal on neuropsychiatric disorders in epilepsy. Patients with antiepileptic drug-induced psychotic disorder were compared to those with psychotic disorders unrelated to antiepileptic drugs assessed over the same period (non-antiepileptic drug induced psychotic disorder group). Univariate comparisons were performed and variables with a value of P < 0.1 were selected for the multivariate logistic regression analysis. The records of 2630 in-patients and outpatients with epilepsy were screened, from which 98 (3.7%) with psychotic disorders were identified. Among these, 14 (14.3%) were diagnosed to have antiepileptic drug-induced psychotic disorder. Excluding one patient who developed psychosis after valproate withdrawal, 76.9% in the antiepileptic drug induced psychotic disorder group were female and the percentage of temporal lobe involvement was higher in the antiepileptic drug induced psychotic disorder group (69.2% versus 38.1%, P < 0.05). Current use of levetiracetam was higher in antiepileptic drug-induced psychotic disorder group (84.6% versus 20.2%, P < 0.01) while use of carbamazepine was higher in the comparator group (15.4% versus 44.0%, P < 0.05). Multivariate logistic regression confirmed four factors associated with antiepileptic drug-induced psychotic disorder: female gender, temporal lobe involvement and use of levetiracetam, and a negative association with carbamazepine. Disorganized behaviours and thinking were more common in the antiepileptic drug-induced psychotic disorder group (100% versus 72.6% and 76.9% versus 38.1%, respectively; P < 0.05). The percentage of continuous treatment with antipsychotic drugs was lower in the antiepileptic drug-induced psychotic disorder group (15.4% versus 66.7%, P < 0.01). No patients experienced a chronic course in antiepileptic drug-induced psychotic disorder group whereas 40.5% did in non-antiepileptic drug induced psychotic disorder (P < 0.05). Our findings indicated that one in seven patients with epilepsy who developed psychosis had antiepileptic drug-induced psychotic disorder. In these patients, female gender, temporal lobe involvement and current use of levetiracetam were significantly associated with antiepileptic drug induced psychotic disorder compared to other types of psychosis, while carbamazepine had a negative association. Disorganized behaviours and thinking were predominant in antiepileptic drug-induced psychotic disorder. Patients with antiepileptic drug-induced psychotic disorder differed from non-antiepileptic drug-induced psychotic disorders in having better outcome.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  AED-induced psychotic disorder; antiepileptic drug; epilepsy; psychosis

Year:  2016        PMID: 27503872     DOI: 10.1093/brain/aww196

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  9 in total

1.  Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study.

Authors:  Vincenzo Belcastro; Laura Rosa Pisani; Silvio Bellocchi; Paolo Casiraghi; Gaetano Gorgone; Marco Mula; Francesco Pisani
Journal:  J Neurol       Date:  2017-03-18       Impact factor: 4.849

2.  Psychotic Disorders in Epilepsy: Do They Differ from Primary Psychosis?

Authors:  Kousuke Kanemoto
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription.

Authors:  Colin B Josephson; Jordan D T Engbers; Nathalie Jette; Scott B Patten; Shaily Singh; Tolulope T Sajobi; Deborah Marshall; Yahya Agha-Khani; Paolo Federico; Aaron Mackie; Sophie Macrodimitris; Brienne McLane; Neelan Pillay; Ruby Sharma; Samuel Wiebe
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

4.  [Epilepsy in the aged : Challenges in diagnostics and treatment].

Authors:  Alexandra Rohracher; Eugen Trinka
Journal:  Z Gerontol Geriatr       Date:  2021-04-23       Impact factor: 1.281

5.  Phenytoin Augmentation of Levetiracetam Treatment: A Case of Forced Normalization With Emergence of Psychosis.

Authors:  Michael Esang; Vijaya Padma Kotapati; Saeed Ahmed
Journal:  Cureus       Date:  2018-04-05

6.  Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists.

Authors:  Arianna Giorgetti; Francesco Paolo Busardò; Roberta Tittarelli; Volker Auwärter; Raffaele Giorgetti
Journal:  Front Psychiatry       Date:  2020-05-25       Impact factor: 4.157

7.  Individual vulnerabilities to psychosis after antiepileptic drug administration.

Authors:  Nozomi Akanuma; Naoto Adachi; Peter Fenwick; Masumi Ito; Mitsutoshi Okazaki; Koichiro Hara; Ryouhei Ishii; Masanori Sekimoto; Masaaki Kato; Teiichi Onuma
Journal:  BMJ Neurol Open       Date:  2020-08-27

8.  A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.

Authors:  Ciarán Campbell; Mark McCormack; Sonn Patel; Caragh Stapleton; Dheeraj Bobbili; Roland Krause; Chantal Depondt; Graeme J Sills; Bobby P Koeleman; Pasquale Striano; Federico Zara; Josemir W Sander; Holger Lerche; Wolfram S Kunz; Kari Stefansson; Hreinn Stefansson; Colin P Doherty; Erin L Heinzen; Ingrid E Scheffer; David B Goldstein; Terence O'Brien; David Cotter; Samuel F Berkovic; Sanjay M Sisodiya; Norman Delanty; Gianpiero L Cavalleri
Journal:  Epilepsia       Date:  2022-04-01       Impact factor: 6.740

9.  Postictal Psychosis in Epilepsy: A Clinicogenetic Study.

Authors:  Vera Braatz; Helena Martins Custodio; Simona Balestrini; Sanjay M Sisodiya; Costin Leu; Luigi Agrò; Baihan Wang; Stella Calafato; Genevieve Rayner; Michael G Doyle; Christian Hengsbach; Francesca Bisulli; Yvonne G Weber; Antonio Gambardella; Norman Delanty; Gianpiero Cavalleri; Jacqueline Foong; Ingrid E Scheffer; Samuel F Berkovic; Elvira Bramon
Journal:  Ann Neurol       Date:  2021-08-03       Impact factor: 11.274

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.